<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0603245020
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Roxban
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIVAROXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        179.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AJA PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1916]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Roxban contains the active substance rivaroxaban and is used in adults to&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevent blood clots in the veins after a hip or knee replacement operation. Your doctor has prescribed this medicine for you because after an operation you are at an increased risk of getting blood clots.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels of your lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of your legs and/or lungs.</p><p>&nbsp;</p><p>Roxban belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Roxban: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are bleeding excessively</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g. stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a liver disease which leads to an increased risk of bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast-feeding</p><p><strong>Do not take </strong><strong>Roxban</strong> <strong>and tell your doctor</strong> if any of these apply to you.</p><p>&nbsp;</p><p><strong>Warnings and Precautions </strong></p><p>Talk to your doctor or pharmacist before taking Roxban.</p><p>&nbsp;</p><p><strong>Take special care with </strong><strong>Roxban</strong></p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an increased risk of bleeding, as could be the case in situations such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moderate or severe kidney disease, since your kidney function may affect the amount of medicine that works in your body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section &ldquo;Other medicines and Roxban&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding disorders&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; very high blood pressure, not controlled by medical treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus) or tumours located in the stomach or bowels or genital tract or urinary tract</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a problem with the blood vessels in the back of your eyes (retinopathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a prosthetic heart valve</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your doctor determines that your blood pressure is unstable or another treatment or surgical procedure to remove the blood clot from your lungs is planned.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>If any of the above apply to you, tell your doctor </strong>before you take Roxban. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.&nbsp;</p><p>&nbsp;</p><p><strong>If you need to have an operation </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is very important to take Roxban before and after the operation exactly at the times you have been told by your doctor.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your operation involves a catheter or injection into your spinal column (e.g. for epidural or spinal anaesthesia or pain reduction):&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it is very important to take Roxban exactly at the times you have been told by your doctor&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents </strong></p><p>Roxban 10 mg tablets are <strong>not recommended for people under 18 years of age.</strong> There is not enough information on their use in children and adolescents.</p><p><strong>Other medicines and Roxban</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p><strong>&nbsp;&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole tablets (used to treat Cushing&rsquo;s syndrome - when the body produces an excess of cortisol)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for bacterial infections (e.g. clarithromycin, erythromycin)&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some anti-viral medicines for HIV / AIDS (e.g. ritonavir)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol)&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dronedarone, a medicine to treat abnormal heart beat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))</p><p>&nbsp;</p><p><strong>If any of the above apply to you, tell your doctor</strong> before taking Roxban, because the effect of Roxban may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.&nbsp;</p><p>If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.<strong> </strong></p><p><strong>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort (<em>Hypericum perforatum</em>), a herbal product used for depression</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin, an antibiotic</p><p><strong>&nbsp;</strong></p><p><strong>If any of the above apply to you, tell your doctor</strong> before taking Roxban, because the effect of Roxban may be reduced. Your doctor will decide, if you should be treated with Roxban &nbsp;and if you should be kept under closer observation.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding </strong></p><p>Do not take Roxban if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Roxban. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Roxban may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4 &rdquo;Possible side effects&rdquo;). You should not drive, ride a bicycle or use any tools or machines if you are affected by these symptoms.&nbsp;</p><p>&nbsp;</p><p><strong>Roxban contains lactose and sodium&nbsp; </strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &ldquo;sodium free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prevent blood clots in the veins after a hip or knee replacement operation The recommended dose is one tablet Roxban 10 mg once a day<strong>.&nbsp; </strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs, and for preventing blood clots from re-occurring</p><p>After at least 6 months blood clot treatment, the recommended dose is either one 10 mg tablet once a day or one 20 mg tablet once a day. Your doctor has prescribed you Roxban 10 mg once a day.&nbsp;</p><p>&nbsp;</p><p>Swallow the tablet preferably with water.</p><p><strong>Roxban</strong> can be taken with or without food.</p><p><strong>When to take </strong><strong>Roxban</strong></p><p>Take the tablet every day until your doctor tells you to stop.&nbsp;</p><p>Try to take the tablet at the same time every day to help you to remember it. Your doctor will decide how long you must continue treatment.&nbsp;</p><p>&nbsp;</p><p>To prevent blood clots in the veins after a hip or knee replacement operation:</p><p>Take the first tablet 6 - 10 hours after your operation. <strong>&nbsp;</strong></p><p>If you have had a major hip operation you will usually take the tablets for 5 weeks.&nbsp;</p><p>If you have had a major knee operation<strong> </strong>you will usually take the tablets for 2 weeks.</p><p>&nbsp;</p><p><strong>If you take more Roxban than you should </strong></p><p>Contact your doctor immediately if you have taken too many Roxban tablets. Taking too much Roxban increases the risk of bleeding.&nbsp;</p><p><strong>If you forget to take Roxban</strong></p><p>If you have missed a dose, take it as soon as you remember. Take the next tablet on the following day and then carry on taking a tablet once a day as normal.&nbsp;</p><p>Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking Roxban</strong></p><p>Do not stop taking Roxban without talking to your doctor first, because Roxban prevents the development of a serious condition.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Roxban can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Like other similar medicines to reduce the formation of blood clots, Roxban may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately if you experience any of the following side effects: </strong></p><p><strong>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of bleeding </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into the brain or inside the skull (symptoms can include headache, one-sided weakness, vomiting, seizures, decreased level of consciousness, and neck stiffness. A serious medical emergency. Seek medical attention immediately!)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long or excessive bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may decide to keep you under closer observation or change the treatment.&nbsp;</p><p>&nbsp;</p><p><strong>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of severe skin reactions </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/toxic epidermal necrolysis).&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a drug reaction that causes rash, fever, inflammation of internal organs, blood abnormalities and systemic illness (DRESS syndrome).&nbsp;</p><p>The frequency of these side effects is very rare (up to 1 in 10,000 people).</p><p>&nbsp;</p><p><strong>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of severe allergic reactions </strong></p><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure.&nbsp;</p><p>The frequencies of severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100 people).</p><p>&nbsp;</p><p><strong>Overall list of possible side effects </strong></p><p><strong>Common </strong>(may affect up to 1 in 10 people)<strong> </strong>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into the eye (including bleeding from the whites of the eyes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into tissue or a cavity of the body (haematoma, bruising)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coughing up blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the skin or under the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding following an operation&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oozing of blood or fluid from surgical wound</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in the limbs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the limbs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired function of the kidneys (may be seen in tests performed by your doctor)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache, indigestion, feeling or being sick, constipation, diarrhea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (symptoms may be feeling dizzy or fainting when standing up)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased general strength and energy (weakness, tiredness), headache, dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, itchy skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show an increase in some liver enzymes&nbsp;</p><p>&nbsp;</p><p><strong>Uncommon (</strong>may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into the brain or inside the skull (see above, signs of bleeding)&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into a joint causing pain and swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombocytopenia (low number of platelets, which are cells that help blood to clot)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions, including allergic skin reactions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired function of the liver (may be seen in tests performed by your doctor)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets<em> </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling unwell&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; faster heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding into a muscle</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cholestasis (decreased bile flow), hepatitis incl. hepatocellular injury (inflamed liver incl. liver injury)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin and eye (jaundice)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; localised swelling</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)</p><p><strong>&nbsp;</strong></p><p><strong>Very rare</strong> (may affect up to 1 in 10,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accumulation of eosinophils, a type of white granulocytic blood cells that cause inflammation in the lung (eosinophilic pneumonia)</p><p><strong>&nbsp;</strong></p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure after a severe bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the kidney sometimes with presence of blood in urine leading to inability of the kidneys to work properly (anticoagulant-related nephropathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>- Do not use this medicine after the expiry date which is stated on carton, bottle and blister foil after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>- Do not store above 30&deg;C</p><p>-Do not use this medicine if you notice that the pack is damaged or shows signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste.</p><p>Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>What Roxban contains: </u></p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Roxban 10 mg Filmcoated Tablets:</p><p>The active substance is Rivaroxaban. Each tablets contains Microcrystalline Cellulose, Croscarmellose sodium, Lactose Monohydrate, Hypromellose, Sodium Laurilsulfate, Magnesium Stearate, Coating material for Coating material for 10 mg Opadry Pink 03F240042.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Roxban looks like and contents of the pack:

Roxban10 mg film coated tablets supplied as pink, round, bi-convex film-coated tablets, engraved with “10” on one side, plain on the other side.



Roxban 10 mg available in blister packs containing 30 tablets in one unit cartoon
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>AJA Pharmaceutical Industries Company Ltd.,</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hail Industrial City MODON, Street No 32</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PO Box 6979, Hail 55414</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kingdom of Saudi Arabia.</p><p><strong>&nbsp; Manufacturer: </strong></p><p>AJA Pharmaceutical Industries Company Ltd.,</p><p>Hail Industrial City MODON, Street No 32</p><p>PO Box 6979, Hail 55414</p><p>Kingdom of Saudi Arabia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This Leaflet approved in August 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي روكسبان على المادة الفعالة ريفاروكسابان ويستخدم لدى المرضى البالغين لعلاج الحالات التالية:</p><p>لمنع تكوُّن الجلطات الدموية في الأوردة بعد إجراء جراحات استبدال الورك أو الركبة. لثد وصف طبيبك هذا الدواء لك لأنك بعد العملية تكون في خطر متزايد للإصابة بجلطات دموية.</p><p>-&nbsp;لعلاج الجلطات الدموية في أوردة الساقين (التجلط الوريدي العميق) وفي الأوعية الدموية بالرئتين (الانصمام الرئوي)، ولمنع تكرار حدوث الجلطات الدموية في الأوعية الدموية بالساقين و/أو الرئتين.</p><p dir="RTL">ينتمي روكسبان إلى مجموعة من الأدوية تعرف باسم الأدوية المانعة لتجلط الدم. يعمل هذا الدواء من خلال وقف مفعول العوامل التي تعمل على تجلط الدم (عامل Xa ) وبالتالي يقلل من ميل الدم إلى تكوين الجلطات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استعمال روكسبان</strong></p><p>-&nbsp;إذا لديك حساسية تجاه ( ريفاروكسابان) أو أي من مكونات هذا الدواء الأخرى (مذكورة في القسم 6).</p><p>-&nbsp;إذا كنت تعاني من نزيف زائد.</p><p>-&nbsp;إذا كنت تعاني من مرض أو حالة بأحد أعضاء الجسم تزيد من خطر حدوث نزيف خطير (على سبيل المثال قرحة المعدة أو إصابة أو نزيف في الدماغ أوإجراء جراحة حديثة بالمخ أو العينين).</p><p>-&nbsp;إذا كنت تتناول أدوية لمنع تجلط الدم (على سبيل المثال وارفارين أو دابيجاتران&nbsp;أو أبيكسابان أو هيبارين)، إلا في حالة تغيير العلاج المضاد للتجلط أو من خلال استخدام هيبارين عن طريق أنبوب داخل الوريد أو الشريان لإبقائه مفتوحًا (لمنع انسداده).</p><p>-&nbsp;إذا كنت تعاني من مرض في الكبد يُؤدي إلى زيادة خطر حدوث نزيف.</p><p>-&nbsp;إذا كنتِ حاملًا أو تمارسين الرضاعة الطبيعية.</p><p><strong>لا تتناول </strong><strong>روكسبان </strong><strong>في حال انطبق عليك أي مما سـبق وتحدث إلى طبيبـك أو الصيدلي قبل تناول هـذا الدواء</strong><strong> . </strong></p><p><strong>&nbsp;</strong></p><p><strong>تحذيرات</strong><strong> واحتياطات</strong>&nbsp;</p><p>استشر طبيبك أو الصيدلي قبل تناول روكسبان.</p><p>&nbsp;</p><p><strong>كن حذرا عند استعمال &nbsp;</strong><strong>روكسبان </strong><strong>في الحالات التالية:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك خطر متزايد من الإصابة بنزيف، على النحو الوارد في الحالات مثل:&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة أمراض الكلى المتوسطة أو الشديدة، حيث يمكن أن تؤثر وظائف الكلى على كمية الدواء التي تعمل داخل الجسم.&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية أخرى لمنع تجلط الدم (مثل؛ وارفارين أو دابيجاتران أو أبيكسابان أو هيبارين)، عندما يتم تغيير العلاج المضاد للتجلط أو من خلال استخدام هيبارين عن طريق أنبوب داخل الوريد أو الشريان لإبقائه مفتوحًا (لمنع انسداده) &quot; أنظر الى فقرة روكسبان والأدوية الاخرى &quot; .</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة اضطرابات نزف الدم.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة ضغط الدم المرتفع جدًا، لا يمكن السيطرة عليه بالعلاج الطبي.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة أمراض المعدة أو الأمعاء التي قد تؤدي إلى نزيف، على سبيل المثال التهاب الأمعاء أو المعدة أو التهاب المريء، على سبيل المثال بسبب مرض الارتجاع المعدي المريئي (يحدث هذا المرض عندما يتدفق حمض المعدة صاعدًا إلى المريء) ، أو الأورام الموجودة في المعدة أو الأمعاء أو الجهاز التناسلي أو المسالك البولية.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود مشكلة في الأوعية الدموية الموجودة في الجزء الخلفي من العين (اعتلال الشبكية).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;مرض رئوي تكون فيه الشعب موسعة ومليئة بالصديد (توسع القصبات)، أو حدوث نزيف سابق من الرئة.</p><p>&nbsp;</p><p>&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد قمت بزراعة صمام قلب اصطناعي.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أن لديك مرضاً يسمى بمتلازمة مضاد الفوسفوليبيد (اضطراب في الجهاز المناعي الذي يسبب زيادة خطر جلطات الدم) أخبر طبيبك الذي سيقرر ما إذا كان العلاج قد يحتاج إلى تغيير.&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدد طبيبك بأن ضغط الدم لديك غير مستقر أو أنه من المخطط تلقي علاج أو إجراء جراحي آخر لإزالة الجلطة الدموية من الرئتين.</p><p><strong>إذا انطبق عليك أي عرض من الأعراض السابقة، أخبر طبيبك&nbsp;قبل تناول </strong><strong>روكسبان</strong><strong> سيقرر طبيبك ما إذا كان يجب علاجك بهذا الدواء وما إذا كان يتوجب وضعك تحت الملاحظة عن قرب.</strong></p><p><strong>إذا كنت بحاجة إلى إجراء عملية جراحية :</strong></p><p>-&nbsp;من المهم جدًا تناول روكسبان قبل العملية وبعدها تمامًا حسب الموعد الذي يحدده طبيبك .</p><p>-&nbsp;إذا كانت العملية الجراحية تستلزم إجراء قسطرة أو حقن في العمود الفقري (على سبيل المثال التخدير فوق الجافية أو النخاع الشوكي أو الحقن التي يتم إعطاؤها لتقليل الألم) :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم جدًا تناول روكسبان بالضبط في الأوقات التي أخبرك بها طبيبك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر الطبيب على الفور إذا أصبت بتنميل أو ضعف بالساقين أو مشاكل بالأمعاء أو المثانة بعد نهاية عملية التخدير، لأنه من الضروري الحصول على الرعاية العاجلة في مثل هذه الحالات .</p><p>&nbsp;</p><p><strong>الأطفال والمراهقون</strong></p><p>&nbsp;ينصح بعدم استخدام روكسبان للأطفال والمراهقين أقل من 18عاماً. لا توجد معلومات كافية حول الاستخدام لدى المرضى من الأطفال والمراهقين.</p><p>&nbsp;</p><p><strong>تناول </strong><strong>روكسبان </strong><strong>مع أدوية أخرى : </strong></p><p>أخبر طبيبك أو الصيدلي&nbsp; إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى ، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.</p><p><strong>-&nbsp;إذا كنت تتناول :</strong></p><p>&bull;&nbsp;بعض الأدوية التي تستخدم لعلاج العدوى الفطرية (مثل فلوكونازول وإيتراكونازول وفوريكونازول وبوساكونازول)، إلا إذا كانت تستخدم وتوضع على الجلد فقط.</p><p>&bull; أقراص&nbsp;كيتوكونازول (دواء يُستخدم في علاج مرض متلازمة كوشينج &ndash; عندما يزيد الجسم في إنتاج كمية كبيرة من هرمون الكورتيزول).</p><p dir="RTL">&bull;&nbsp;بعض الأدوية التي تستخدم في حالات العدوى البكتيرية (مثل كلاريثروميسين وإريثروميسين).&nbsp;</p><p dir="RTL">&nbsp;&bull;&nbsp;بعض الأدوية المضادة لفيروس النقص المناعي البشري / الإيدز (متلازمة النقص المناعي المكتسب) HIV / AIDS مثل (ريتونافير)</p><p>&bull;&nbsp;الأدوية الأخرى التي تستخدم لتقليل تجلط الدَّم (مثل إينوكسابارين وكلوبيدوجريل أو مضادات فيتامين ك مثل وارفارين واكينوكيومارول).</p><p>&bull;&nbsp;الأدوية المضادة للالتهاب والأدوية المسكنة للألم (مثل نابروكسين أو حمض الأسيتيل ساليسيلك).</p><p>&bull;&nbsp;الأدوية التي تستخدم لعلاج ضربات القلب غير الطبيعية (مثل درونيدارون).</p><p dir="RTL">&bull;&nbsp;بعض الأدوية التي تستخدم لعلاج الاكتئاب (مثبطات إعادة امتصاص السيروتونين الانتقائية &quot;SSRIs&quot; أو مثبطات استرداد السيروتونين والنورابينفرين &quot;SNRIs&quot;).</p><p><strong>&nbsp;أخبر طبيبك&nbsp; قبل تناول </strong><strong>روكسبان </strong><strong>إذا انطبق عليك أي من الأعراض السابقة، لأن هذا قد يؤثر على زيادة فعالية </strong><strong>روكسبان</strong><strong> سيقرر الطبيب المعالج ما إذا كان يجب علاجك بهذا الدواء وإذا كان يجب ابقاؤك تحت الملاحظة عن قرب أم لا.</strong></p><p>إذا اعتقد طبيبك أنك في خطر متزايد للإصابة بقرحة في المعدة أو الأمعاء ، فقد يستخدم أيضًا علاجًا وقائيًا للقرحة.</p><p>&nbsp;</p><p><strong>أخبر طبيبك ، إذا كنت تتناول أي من الأدوية التالية:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية التي تستخدم لعلاج مرض الصرع (فينيتوين وكاربامازيبين وفينوباربيتال).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة القديس جون، منتج عشبي يتم استخدامه لعلاج الاكتئاب.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (مضاد حيوي).</p><p><strong>إذا انطبق عليك أي من الأعراض السابقة، أخبرطبيبك قبل تناول </strong><strong>روكسبان</strong><strong>، لأن هذا قد يؤثر في التقليل من فعالية </strong><strong>روكسبان</strong><strong>. سيقرر الطبيب المعالج ما إذا كان يجب علاجك بهذا الدواء وإذا كان يجب أن يبقيك تحت الملاحظة عن قرب أم لا.</strong></p><p>&nbsp;</p><p><strong>الحمل والرضاعة </strong></p><p>يحظر عليكِ تناول روكسبان إذا كنتِ حاملًا أو تمارسين الرضاعة الطبيعية. إذا كان هناك احتمال أن تصبحين حاملًا، استخدمي وسيلة فعالة لمنع الحمل أثناء فترة العلاج روكسبان إذا أصبحتِ حاملاً أثناء تناول هذا الدواء، أخبري الطبيب المعالج لكِ فورًا والذي سيحدد طريقة العلاج المناسبة لك.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p>يمكن أن يسبب روكسبان دوخة (أثر جانبي شائع) أو حالات إغماء (أثر جانبي غير شائع) (انظر القسم 4 ، &quot;الآثار الجانبية المحتملة&quot;). يجب عليك تجنُّب قيادة السيارات أو استخدام الآلات إذا شعرت بأي تأثير من هذه الأعراض.</p><p><strong>يحتوي روكسبان على اللاكتوز و الصوديوم </strong></p><p>إذا أخبرك طبيبك أن لديك حساسية تجاه بعض السكريات ، فاتصل بطبيبك قبل تناول هذا الدواء.</p><p>يحتوي هذا الدواء على أقل من 1 مليمول صوديوم ( 23 ملجم) لكل قرص ، أي بشكل أساسي &quot; خالي من الصوديوم&quot; .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً تناول هذا الدواء بدقة كما يوصي به طبيبك. إذا كنت غير متأكد يجب المراجعة مع طبيبك أو الصيدلي.</p><p dir="RTL"><strong>ما هي الكمية التي يجب تناولها</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمنع حدوث الجلطات الدموية في الأوردة بعد عملية استبدال مفصل الورك أو الركبة الجرعة الموصي بها هي قرص واحد روكسبان<strong> </strong>10 ملجم مرة واحدة يومياً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الجلطات الدموية في أوردة السيقان و الجلطات الدموية في الأوعية الدموية للرئة، و لمنع تكرار حدوث جلطات دموية بعد 6 أشهر على الأقل من علاج جلطة الدم، الجرعة الموصى بها هي إما قرص واحد 10 ملجم مرة واحدة يومياً أو قرص واحد 20 ملجم مرة واحدة يومياً. وقد وصف لك الطبيب روكسبان<strong> </strong>10 ملجم مرة واحدة في اليوم</p><p dir="RTL">يُفضل أن يُبلع القرص مع الماء.</p><p dir="RTL">يمكن تناول روكسبان<strong> </strong>مع أو بدون طعام.</p><p>&nbsp;</p><p><strong>موعد ومدة تناول </strong><strong>روكسبان</strong><strong>:</strong></p><p>- استمر في تناول روكسبان<strong> </strong>ما لم يخبرك الطبيب المعالج لك بإيقاف العلاج.</p><p>- حاول أن تتناول القرص (الأقراص) في نفس الوقت كل يوم فهذا يساعدك على تذكر الموعد. سيقرر الطبيب المعالج لك المدة الزمنية اللازمة للاستمرار في تناول العلاج.</p><p>- في حالة استخدام الدواء لمنع تكوُّن الجلطات الدموية في الأوردة بعد إجراء جراحات استبدال الورك أو الركبة:</p><p>&nbsp;يجب أن تتناول القرص الأول بعد 6 إلى 10 ساعات من إجراء الجراحة.</p><p>إذا كنت قد خضعت إلى جراحة كبرى بالورك فستتناول عادةً الدواء لمدة 5 أسابيع.</p><p>إذا كنت قد خضعت إلى جراحة كبرى بالركبة فستتناول عادةً الأقراص لمدة أسبوعين.</p><p>&nbsp;</p><p>إ<strong>ذا تناولت كمية أكثر مما يجب من روكسبان</strong></p><p>استشر طبيبك فورًا، إذا كنت قد تناولت كمية كبيرة من روكسبان ، تناول كمية كبيرة من روكسبان<strong> </strong>يزيد من خطر الإصابة بنزيف.</p><p>&nbsp;</p><p><strong>إذا نسيت تناول </strong><strong>روكسبان</strong></p><p>إذا نسيت تناول إحدى الجرعات، فتناولها بمجرد تذكرك لها. تناول الجرعة التالية في اليوم التالي ثم استمر في تناول قرص واحد يوميًا على النحو المعتاد. لا تتناول جرعة مضاعفة لتعويض جرعة نسيتها.</p><p>&nbsp;</p><p><strong>إذا توقفت عن تناول روكسبان</strong></p><p>يجب عدم التوقف عن تناول روكسبان بدون استشارة طبيبك أولاً، لأن روكسبان يساهم في الوقاية والعلاج من بعض الحالات الخطيرة. إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاستشر طبيبك أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يسبب روكسبان<strong> </strong>، مثله مثل كافة الأدوية، آثار جانبية على الرغم من عدم حدوثها لجميع المرضى.</p><p>كما يمكن أن يسبب <strong><em>روكسبان</em></strong><strong> </strong>، مثل الأدوية المشابهة الأخرى (الأدوية المانعة لتجلط الدم)، نزيفًا والذي قد يكون من المحتمل مهددًا لحياة المريض. قد يؤدي النزيف الشديد إلى حدوث هبوط مفاجئ في ضغط الدَّم (صدمة). وقد لا يكون هذا النزيف واضحًا في بعض الحالات.</p><p><strong>&nbsp;</strong></p><p><strong>أخبر طبيبك المعالج لك فورًا، </strong>إذا تعرضت لأي من الآثار الجانبية التالية :</p><p><strong>- علامات نزيف </strong></p><p dir="RTL">- نزيف في المخ أو داخل الجمجمة (يمكن أن تشمل الأعراض الصداع والضعف في جانب واحد ، القيء ،تشنجات ، انخفاض مستوى الوعي وتيبس الرقبة. حالة طبية طارئة خطيرة. اطلب العناية الطبية على الفور!)</p><p dir="RTL">&nbsp;- نزيف طويل أو مفرط</p><p dir="RTL">&nbsp;- ضعف استثنائي ، إرهاق ، شحوب ، دوار ، صداع ، إنتفاخ غير مبرر ، ضيق تنفس ، ألم في الصدر أو ذبحة صدرية</p><p dir="RTL">&nbsp;قد يقرر طبيبك إبقائك تحت الملاحظة أو تغيير العلاج.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>- علامات ردود فعل جلدية شديدة</strong></p><p>-&nbsp;طفح جلدي شديد منتشر بالجسم ،أوبثور أو آفات مخاطية، على سبيل المثال في الفم أو العينين (متلازمة ستيفنز جونسون/نخر البشرة السمي).</p><p dir="RTL">-&nbsp;تفاعل دوائي يؤدي إلى الإصابة بطفح جلدي وحمى والتهاب الأعضاء الداخلية واضطرابات الدم وتعب في مختلف أجهزة الجسم (متلازمة طفح جلدي بسبب الأدوية مع فرط الحمضات والأعراض الجهازية &quot;DRESS&quot;). يحدث هذا التأثير الجانبي بصورة نادرة جدًّا (يؤثر على مريض واحد من بين 10.000 مريض).</p><p>&nbsp;</p><p><strong>- علامات الحساسية الشديدة </strong></p><p>-&nbsp;تورّم بالوجه أو الشَّفَتين أو الفم أو الحلق أو صعوبة في البلع وشرى &quot;ارتكاريا&quot; وصعوبة في التنفس وهبوط مفاجئ في ضغط الدم. يحدث هذا التأثير الجانبي بصورة نادرة جدًّا (تفاعلات الحساسية والتي تشمل صدمة حساسية، قد يوثر على مريض واحد من بين 10,000 مريض) وغير شائعة (الوذمة الوعائية والوذمة التحسسية ؛ قد يوثر على مريض واحد من بين 100 شخص).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>قائمة شاملة للآثار الجانبية المُحتمَلة:</strong></p><p><strong>آثار جانبية شائعة&nbsp;(قد تؤثر على مريض واحد من بين كل 10 مرضى):</strong></p><p>-&nbsp;انخفاض في خلايا الدم الحمراء الذي يسبب شحوب البشرة مما يؤدي إلى ضعف أو ضيق بالتنفس.</p><p>-&nbsp;نزيف بالمعدة أو الامعاء ونزيف في الأجهزة البولية التناسلية (تشمل نزول الدم مع البول ونزيف غزير أثناء فترة الحيض) نزيف بالأنف ونزيف باللثة.</p><p>-&nbsp; نزيف داخل العين (بما في ذلك نزيف في الأجزاء البيضاء من العينين).</p><p>-&nbsp;نزيف داخلي في الأنسجة أو التجويف الداخلي للجسم (تجمع دموي، كدمات).</p><p>-&nbsp;كحة مصحوبة بدم.</p><p>-&nbsp;نزيف بالجلد أو بالأنسجة الموجودة تحت الجلد.</p><p>-&nbsp;نزيف بعد إجراء عملية جراحية.&nbsp;</p><p>-&nbsp;نزول دم أو سوائل من جرح العملية الجراحية.</p><p>-&nbsp;تورم في الأطراف.</p><p>-&nbsp;ألم في الأطراف.</p><p>-&nbsp;خلل بوظائف الكلى (يمكن ملاحظتها من خلال الاختبارات التي يشرف عليها طبيبك ).</p><p>-&nbsp;حُمى.</p><p>-&nbsp;ألم بالمعدة أو عسر هضم أو شعور بالإعياء أو المرض، إمساك وإسهال.</p><p>-&nbsp;انخفاض ضغط الدَّم (قد تشتمل الأعراض على الشعور بدوخة أو إغماء عند الوقوف).</p><p>-&nbsp;ضعف عام بالقوة والطاقة (ضعف وتعب) صداع ودوخة.</p><p>-&nbsp;طفح جلدي، حكة في الجلد .</p><p>-&nbsp;قد تظهر اختبارات الدم ارتفاع في بعض انزيمات الكبد.</p><p>&nbsp;</p><p><strong>آثار جانبية غير شائعة&nbsp;(قد تُؤثر على مريض واحد من بين كل 100 مريض)</strong></p><p>-&nbsp;نزيف في الدماغ أو داخل الرأس ( انظر اعلاه ، علامات النزيف)</p><p>-&nbsp;نزيف بأحد المفاصل مما يسبب ألم وتورم.</p><p>-&nbsp;انخفاض بالصفيحات (انخفاض بعدد الصفائح الدَّموية، وهي الخلايا التي تساعد على تجلط الدم)</p><p>-&nbsp;تفاعلات حساسية (بما في ذلك تفاعلات حساسية بالجلد).</p><p>-&nbsp;ضعف وظائف الكبد (قد يظهر هذا في الاختبارات التي يجريها طبيبك ).</p><p>-&nbsp;قد تظهر اختبارات الدم ارتفاع في مستوى البيليروبين وبعض انزيمات البنكرياس أو الكبد أو ارتفاع في عدد الصفائح الدموية.</p><p>-&nbsp;إغماء.</p><p>-&nbsp;شعور بالإعياء (توعُّك).</p><p>-&nbsp;تسارع ضربات القَلْب.</p><p>-&nbsp;جُفافُ الفَم.</p><p>-&nbsp;شرى .</p><p>&nbsp;</p><p><strong>آثار جانبية نادرة&nbsp;(قد تُؤثر على مريض واحد من بين كل 1,000 مريض):</strong></p><p>-&nbsp;نزيف بالعضل.</p><p>-&nbsp;ركود صفراوي (انخفاضٌ في تدفّق العصارة الصفراوية) التهاب الكبد بما في ذلك اصابة الخلايا الكبدية (التهاب الكبد بما في ذلك الإصابات الكبدية).</p><p>-&nbsp;اصفرار الجلد والعينين (يرقان).</p><p>-&nbsp;ورم موضعي.</p><p dir="RTL">-&nbsp;تجمع دموي (ورم دموي) في الفخذ نتيجة حدوث مضاعفات من الإجراء القلبي عندما يتم إدخال قسطرة داخل شريان الساق (تمدد الأوعية الدموية الكاذب).</p><p dir="RTL"><strong>نادرة جدًا (قد تظهر لدى حتى 1 من بين 10000 شخص) </strong></p><p dir="RTL">&nbsp;تراكم الحمضات ، وهي نوع من خلايا الدم البيضاء المحببة التي تسبب التهابًا في الرئة (الالتهاب الرئوي اليوزيني)</p><p>&nbsp;</p><p><strong>آثار جانبية غير معروف معدّل تكرارها&nbsp;</strong>(لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):</p><p>-&nbsp;فشل كلوي بعد الإصابة بنزيف شديد.</p><p>-نزيف في الكلى في بعض الأحيان مع وجود دم في البول مما يؤدي إلى عدم قدرة الكلى على العمل بشكل صحيح (اعتلال الكلية المرتبط بمضادات التخثر).</p><p>-&nbsp;ارتفاع الضغط داخل عضلات الساقين والذراعين بعد النزيف، الذي يؤدي إلى ألم أو تورم أو تغير في الاحساس أو تنميل أو شلل (متلازمة الحيز &quot;زيادة الضغط داخل حَيِّز بالجسم&quot; بعد النزيف).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- &nbsp;يحفظ هذا الدواء بعيدًا عن مرأى ومتناول أيدي الأطفال.</p><p dir="RTL">&nbsp;- لا تستخدم هذا المستحضر بعد تاريخ انتهاء الصلاحية المدون على العبوة الخارجية والملصق بعد الرمز &quot;EXP&quot; الذي يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">- يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">- لا تستخدم هذا المستحضر إذا لاحظت أن العبوة تالفة أو تظهر عليها علامات العبث.</p><p dir="RTL">&nbsp;-لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية.</p><p dir="RTL">اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. تساعد هذه التدابير على حماية البيئة.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>- محتويات العبوة وغيرها من المعلومات</strong></p><p dir="RTL"><u>ما هي محتويات روكسبان</u><u> </u></p><p dir="RTL">&nbsp;روكسبان 10 ملجم أقراص مغلفة: &nbsp;</p><p dir="RTL">المادة الفعالة هي ريفاروكسابان. يحتوي كل قرص على مايكروكرستلين سيليلوز ، كروسكارميلوز صوديوم ، لاكتوز مونوهيدريت ، هيبروميلوز ، صوديوم لوريل سلفيت ، مغنيسيوم سيتيريت ، أوبادري (وردي &nbsp;03F240042).</p><p dir="RTL">.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>يف يبدو المنتج وما هي محتويات العبوة </u></p><p dir="RTL">روكسبان10 ملجم أقراص مغلفة متوفرة على شكل أقراص وردية ، مستديرة ، ثنائية التحدب ، مغلفة بطبقة رقيقة ، منقوشة &nbsp;بـ &quot;10&quot; على جانب واحد فقط.</p><p dir="RTL">روكسبان10 ملجم متوفر في عبوات بها شرائط تحتوي على 30 قرص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق </strong></p><p dir="RTL">شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">المدينة الصناعية مدن بحائل ، شارع رقم 32</p><p dir="RTL">ص.ب. 6979، حائل 55414</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL"><strong>الشركة المصنعة: </strong></p><p dir="RTL">شركة أجا للصناعات الدوائية المحدودة</p><p dir="RTL">المدينة الصناعية مدن بحائل ، شارع رقم 32</p><p dir="RTL">ص.ب. 6979، حائل 55414</p><p dir="RTL">المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذة النشرة في أغسطس 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROXBAN 10 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROXBAN 10 mg tablets Each film coated tablet contains 10 mg of Rivaroxaban
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ROXBAN 10 mg film coated tablets:
Pink, round, bi-convex film-coated tablets, engraved with “10” on one side, plain on the other
side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1 <u>&nbsp;</u><u>Therapeutic Indications</u></p><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.</p><p>Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Posology</em></p><p><em>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</em></p><p>The recommended dose is 10 mg rivaroxaban taken orally once daily. The initial dose should be taken 6 to 10 hours after surgery, provided that haemostasis has been established .</p><p>The duration of treatment depends on the individual risk of the patient for venous thromboembolism which is determined by the type of orthopaedic surgery.</p><p>&bull; For patients undergoing major hip surgery, a treatment duration of 5 weeks is recommended.</p><p>&bull; For patients undergoing major knee surgery, a treatment duration of 2 weeks is recommended.</p><p>If a dose is missed the patient should take Rivaroxaban immediately and then continue the following day with once daily intake as before.</p><p><em>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE</em></p><p>&nbsp;</p><p>The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE .</p><p>Short duration of therapy (at least 3 months) should be considered in patients with DVT or PE provoked by major transient risk factors (i.e. recent major surgery or trauma). Longer duration of therapy should be considered in patients with provoked DVT or PE not related to major transient risk factors, unprovoked DVT or PE, or a history of recurrent DVT or PE .</p><p>When extended prevention of recurrent DVT and PE is indicated (following completion of at least 6 months therapy for DVT or PE), the recommended dose is 10 mg once daily. In patients in whom the risk of recurrent DVT or PE is considered high, such as those with complicated comorbidities, or who have developed recurrent DVT or PE on extended prevention with Rivaroxaban 10 mg once daily, a dose of Rivaroxaban 20 mg once daily should be considered .</p><p>The duration of therapy and dose selection should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4) .</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Time period</strong></p></td><td style="vertical-align:top"><p><strong>Dosing schedule</strong></p></td><td style="vertical-align:top"><p><strong>Total daily dose</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Treatment and prevention of recurrent DVT and PE</p></td><td style="vertical-align:top"><p>Day 1 - 21</p></td><td style="vertical-align:top"><p>15 mg twice daily</p></td><td style="vertical-align:top"><p>30 mg</p></td></tr><tr><td style="vertical-align:top"><p>Day 22 onwards</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of recurrent DVT and PE</p></td><td style="vertical-align:top"><p>Following completion of at least 6 months therapy for DVT or PE</p></td><td style="vertical-align:top"><p>10 mg once daily or 20 mg once daily</p></td><td style="vertical-align:top"><p>10 mg</p><p>or 20 mg</p></td></tr></tbody></table><p>&nbsp;</p><p>To support the dose switch from 15 mg to 20 mg after Day 21 a first 4 weeks treatment initiation pack of Rivaroxaban for treatment of DVT/PE is available.</p><p>If a dose is missed during the 15 mg twice daily treatment phase (day 1 - 21), the patient should take Rivaroxaban immediately to ensure intake of 30 mg Rivaroxaban per day. In this case two 15 mg tablets may be taken at once. The patient should continue with the regular 15 mg twice daily intake as recommended on the following day .</p><p>If a dose is missed during the once daily treatment phase, the patient should take Rivaroxaban immediately, and continue on the following day with the once daily intake as recommended. The dose should not be doubled within the same day to make up for a missed dose.</p><p><em>Converting from Vitamin K Antagonists (VKA) to Rivaroxaban</em></p><p>For patients treated for DVT, PE and prevention of recurrence, VKA treatment should be stopped and Rivaroxaban therapy should be initiated once the INR is &le; 2.5 .</p><p>When converting patients from VKAs to Rivaroxaban, International Normalised Ratio (INR) values will be falsely elevated after the intake of Rivaroxaban. The INR is not valid to measure the anticoagulant activity of Rivaroxaban, and therefore should not be used (see section 4.5).</p><p><em>Converting from Rivaroxaban to Vitamin K antagonists (VKA)</em></p><p>&nbsp;</p><p>There is a potential for inadequate anticoagulation during the transition from Rivaroxaban to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Rivaroxaban can contribute to an elevated INR.</p><p>In patients converting from Rivaroxaban to VKA, VKA should be given concurrently until the INR is &ge; 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Rivaroxaban and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Rivaroxaban. Once Rivaroxaban is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).</p><p><em>Converting from parenteral anticoagulants to Rivaroxaban</em></p><p>For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Rivaroxaban 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).</p><p><em>Converting from Rivaroxaban to parenteral anticoagulants</em></p><p>Give the first dose of parenteral anticoagulant at the time the next Rivaroxaban dose would be taken.</p><p><em>Special populations Renal impairment</em></p><p>Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Rivaroxaban is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.4 and 5.2).</p><p>-For the prevention of VTE in adult patients undergoing elective hip or knee replacement surgery, no dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) or moderate renal impairment (creatinine clearance 30- 49 ml/min) (see section 5.2).</p><p>-For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE, no dose adjustment from the recommended dose is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).</p><p>In patients with moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment: patients should be treated with 15 mg twice daily for the first 3 weeks .Thereafter, when the recommended dose is 20 mg once daily, a reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient&#39;s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting (see sections 4.4, 5.1 and 5.2) .</p><p>&nbsp;</p><p>When the recommended dose is 10 mg once daily, no dose adjustment from the recommended dose is necessary.</p><p><em>Hepatic impairment</em></p><p>Rivaroxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).</p><p><em>Elderly population</em></p><p>No dose adjustment (see section 5.2)</p><p><em>Body weight</em></p><p>No dose adjustment (see section 5.2)</p><p><em>Gender</em></p><p>No dose adjustment (see section 5.2)</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Rivaroxaban 10 mg tablets in children aged 0 to 18 years have not been established. No data are available. Therefore, Rivaroxaban 10 mg tablets are not recommended for use in children below 18 years of age.</p><p><u>Method of administration</u> Rivaroxaban is for oral use .</p><p>The tablets can be taken with or without food (see sections 4.5 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Active clinically significant bleeding.
Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.
Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).
 
Pregnancy and breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.</p><p><em>Haemorrhagic risk</em></p><p>As with other anticoagulants, patients taking Rivaroxaban are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Rivaroxaban administration should be discontinued if severe haemorrhage occurs (see section 4.9).</p><p>In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding ,as judged to be appropriate.</p><p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8). In patients receiving Rivaroxaban for VTE prevention following elective hip or knee replacement surgery, this may be done by regular physical examination of the patients, close observation of the surgical wound drainage and periodic measurements of haemoglobin.</p><p>Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.</p><p>Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).</p><p><em>Renal impairment</em></p><p>In patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. Rivaroxaban is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance 15 &lt; ml/min (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p>In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations Rivaroxaban is to be used with caution (see section 4.5).</p><p><em>Interaction with other medicinal products</em></p><p>The use of Rivaroxaban is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).</p><p>Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid (ASA) and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).</p><p><em>Other haemorrhagic risk factors</em></p><p>As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:</p><p>&bull; congenital or acquired bleeding disorders</p><p>&bull; uncontrolled severe arterial hypertension</p><p>&bull; other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)</p><p>&bull; vascular retinopathy</p><p>&bull; bronchiectasis or history of pulmonary bleeding</p><p><em>Patients with cancer</em></p><p>Patients with malignant disease may simultaneously be at higher risk of bleeding and thrombosis. The individual benefit of antithrombotic treatment should be weighed against risk for bleeding in patients with active cancer dependent on tumour location, antineoplastic therapy and stage of disease. Tumours located in the gastrointestinal or genitourinary tract have been associated with an increased risk of bleeding during rivaroxaban therapy.</p><p>In patients with malignant neoplasms at high risk of bleeding, the use of rivaroxaban is contraindicated (see section 4.3).</p><p><em>Patients with prosthetic valves</em></p><p>&nbsp;</p><p>Rivaroxaban should not be used for thromboprophylaxis in patients having recently undergone transcatheter aortic valve replacement (TAVR). Safety and efficacy of Rivaroxaban have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Rivaroxaban provides adequate anticoagulation in this patient population. Treatment with Rivaroxaban is not recommended for these patients.</p><p><em>Patients with antiphospholipid syndrome</em></p><p>Direct acting Oral Anticoagulants (DOACs) including rivaroxaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p><p><em>Hip fracture surgery</em></p><p>Rivaroxaban has not been studied in interventional clinical studies in patients undergoing hip fracture surgery to evaluate efficacy and safety.</p><p><em>Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy</em></p><p>Rivaroxaban is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of Rivaroxaban have not been established in these clinical situations .</p><p><em>Spinal/epidural anaesthesia or puncture</em></p><p>When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post- operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis .The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.</p><p>To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban .Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low (see section 5.2).</p><p>&nbsp;</p><p>At least 18 hours should elapse after the last administration of rivaroxaban before removal of an epidural catheter. Following removal of the catheter, at least 6 hours should elapse before the next rivaroxaban dose is administered.</p><p>If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours.</p><p><u>Dosing recommendations before and after invasive procedures and surgical intervention other</u> <u>than elective hip or knee replacement surgery</u></p><p>If an invasive procedure or surgical intervention is required, Rivaroxaban 10 mg should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician .</p><p>If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.</p><p>Rivaroxaban should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).</p><p><em>Elderly population</em></p><p>Increasing age may increase haemorrhagic risk (see section 5.2).</p><p><em>Dermatological reactions</em></p><p>Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first</p><p>appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.4. <u>&nbsp;</u><u>Interactions with other medicinal products</u></p><p>CYP3A4 and P-gp inhibitors</p><p>Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban Cmax ,with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Rivaroxaban is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp( see section 4.4 .)</p><p>Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold</p><p>&nbsp;</p><p>increase in Cmax .The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).</p><p>Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a</p><p>1.3 fold increase in mean rivaroxaban AUC and Cmax .The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.</p><p>In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in Cmax when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in Cmax when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).</p><p>Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean Cmax .The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).</p><p>Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.</p><p>Anticoagulants</p><p>After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.</p><p>Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4) .</p><p>NSAIDs/platelet aggregation inhibitors</p><p>No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response .</p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid.</p><p>Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P- selectin or GPIIb/IIIa receptor levels.</p><p>&nbsp;</p><p>Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).</p><p>SSRIs/SNRIs</p><p>As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.</p><p>Warfarin</p><p>Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive .</p><p>If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban .</p><p>If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.</p><p>No pharmacokinetic interaction was observed between warfarin and rivaroxaban.</p><p>CYP3A4 inducers</p><p>Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort( Hypericum perforatum ))may also lead to reduced rivaroxaban plasma concentrations. Therefore , concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.</p><p>Other concomitant therapies</p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of</p><p>P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.</p><p>No clinically relevant interaction with food was observed (see section 4.2).</p><p>Laboratory parameters</p><p>&nbsp;</p><p>Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1) .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>Safety and efficacy of Rivaroxaban have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Rivaroxaban is contraindicated during pregnancy (see section 4.3) .</p><p>Women of child bearing potential should avoid becoming pregnant during treatment with rivaroxaban.</p><p><em>Breast-feeding</em></p><p>Safety and efficacy of Rivaroxaban have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Rivaroxaban is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.</p><p><em>Fertility</em></p><p>No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rivaroxaban has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary of the safety profile</em></p><p>The safety of rivaroxaban has been evaluated in thirteen pivotal phase III studies (see Table 1).</p><p>Overall, 69,608 adult patients in nineteen phase III studies and 488 paediatric patients in two phase II and two phase III studies were exposed to rivaroxaban.</p><p>Table 1: Number of patients studied, total daily dose and maximum treatment duration in adult and paediatric phase III studies</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Number of patients*</strong></p></td><td style="vertical-align:top"><p><strong>Total daily dose</strong></p></td><td style="vertical-align:top"><p><strong>Maximum </strong><strong>treatment duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism (VTE) in adult</p></td><td style="vertical-align:top"><p>6,097</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>39 days</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>patients undergoing elective hip or knee replacement surgery</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of VTE in medically ill patients</p></td><td style="vertical-align:top"><p>3,997</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>39 days</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recurrence</p></td><td style="vertical-align:top"><p>6,790</p></td><td style="vertical-align:top"><p>Day 1 - 21: 30 mg Day 22 and onwards: 20 mg</p><p>After at least 6 months: 10 mg or 20 mg</p></td><td style="vertical-align:top"><p>21 months</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of VTE and prevention of VTE recurrence in term neonates and children aged less than 18 years following initiation of standard anticoagulation treatment</p></td><td style="vertical-align:top"><p>329</p></td><td style="vertical-align:top"><p>Body weight-adjusted dose to achieve a similar exposure as that observed in adults treated for DVT with 20 mg rivaroxaban once daily</p></td><td style="vertical-align:top"><p>12 months</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td style="vertical-align:top"><p>7,750</p></td><td style="vertical-align:top"><p>20 mg</p></td><td style="vertical-align:top"><p>41 months</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td style="vertical-align:top"><p>10,225</p></td><td style="vertical-align:top"><p>5 mg or 10 mg respectively, co- administered with either ASA or ASA plus clopidogrel or ticlopidine</p></td><td style="vertical-align:top"><p>31 months</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td style="vertical-align:top"><p>18,244</p></td><td style="vertical-align:top"><p>5 mg co-administered with ASA or 10 mg alone</p></td><td style="vertical-align:top"><p>47 months</p></td></tr><tr><td style="vertical-align:top"><p>3,256**</p></td><td style="vertical-align:top"><p>5 mg co-administered with ASA</p></td><td style="vertical-align:top"><p>42 months</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* Patients exposed to at least one dose of rivaroxaban</p><p>** From the VOYAGER PAD study</p></td></tr></tbody></table><p>The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and &#39;Description of selected adverse reactions&#39; below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).</p><p>&nbsp;</p><p>Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed adult and paediatric phase III studies</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Any bleeding</strong></p></td><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</p></td><td style="vertical-align:top"><p>6.8% of patients</p></td><td style="vertical-align:top"><p>5.9% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of venous thromboembolism in medically ill patients</p></td><td style="vertical-align:top"><p>12.6% of patients</p></td><td style="vertical-align:top"><p>2.1% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of DVT, PE and prevention of recurrence</p></td><td style="vertical-align:top"><p>23% of patients</p></td><td style="vertical-align:top"><p>1.6% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of VTE and prevention of VTE recurrence in term neonates and children aged less than 18 years following initiation of standard anticoagulation treatment</p></td><td style="vertical-align:top"><p>39.5% of patients</p></td><td style="vertical-align:top"><p>4.6% of patients</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td style="vertical-align:top"><p>28 per 100 patient years</p></td><td style="vertical-align:top"><p>2.5 per 100 patient years</p></td></tr><tr><td style="vertical-align:top"><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td style="vertical-align:top"><p>22 per 100 patient years</p></td><td style="vertical-align:top"><p>1.4 per 100 patient years</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td style="vertical-align:top"><p>6.7 per 100 patient years</p></td><td style="vertical-align:top"><p>0.15 per 100 patient years**</p></td></tr><tr><td style="vertical-align:top"><p>8.38 per 100 patient years #</p></td><td style="vertical-align:top"><p>0.74 per 100 patient years*** #</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.</p><p>** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied</p><p>*** A selective approach to adverse event collection was applied # From the VOYAGER PAD study</p></td></tr></tbody></table><p><u>Tabulated list of adverse reactions</u></p><p>The frequencies of adverse reactions reported with Rivaroxabanin adult and paediatric patients are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.</p><p>Frequencies are defined as:</p><p>very common (&ge; 1/10)</p><p>common (&ge; 1/100 to &lt; 1/10)</p><p>uncommon (&ge; 1/1,000 to &lt; 1/100) rare (&ge; 1/10,000 to &lt; 1/1,000) very rare (&lt; 1/10,000)</p><p>not known (cannot be estimated from the available data)</p><p>Table 3: All adverse reactions reported in adult patients in phase III clinical studies or through post-marketing use* and in two phase II and two phase III studies in paediatric patients</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anaemia (incl. respective laboratory parameters)</p></td><td style="vertical-align:top"><p>Thrombocytosis (incl. platelet count increased)A, thrombocytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reaction, dermatitis allergic, angioedema and allergic oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reactions including anaphylactic shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness, headache</p></td><td style="vertical-align:top"><p>Cerebral and intracranial haemorrhage, syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Eye haemorrhage (incl. conjunctival haemorrhage)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension, haematoma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis, haemoptysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipationA, diarrhoea, vomitingA</p></td><td style="vertical-align:top"><p>Dry mouth</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Hepatobiliary</strong><strong> </strong><strong>disorders</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Increase in transaminases</p></td><td style="vertical-align:top"><p>Hepatic impairment, increased bilirubin, increased blood alkaline phosphataseA, increased GGTA</p></td><td style="vertical-align:top"><p>Jaundice, bilirubin conjugated increased (with or without concomitant increase of ALT), cholestasis, hepatitis (incl. hepatocellular injury)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous haemorrhage</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome/Toxic Epidermal Necrolysis, DRESS syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal and</strong><strong> connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremityA</p></td><td style="vertical-align:top"><p>Haemarthrosis</p></td><td style="vertical-align:top"><p>Muscle haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Compartment syndrome secondary to a bleeding</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urogenital tract haemorrhage (incl. haematuria and menorrhagiaB), renal impairment (incl. blood creatinine increased, blood urea increased)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>FeverA, peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</p></td><td style="vertical-align:top"><p>Feeling unwell (incl. malaise)</p></td><td style="vertical-align:top"><p>Localised oedemaA</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased LDHA, increased lipaseA, increased amylaseA</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretionA</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vascular pseudoaneurysmC</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p><p>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</p><p>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)</p><p>* A pre-specified selective approach to adverse event collection was applied in selected phase III studies. The incidence of adverse reactions did not increase and no new adverse drug reaction was identified after analysis of these studies.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p>Due to the pharmacological mode of action, the use of Rivaroxaban may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 &ldquo;Management of bleeding&rdquo;). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4</p><p>&ldquo;Haemorrhagic risk&rdquo;). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.</p><p>&nbsp;</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Rivaroxaban. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p><em>Reporting of suspected adverse reactions</em></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_2" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;margin-left:48.75pt;margin-top:8.6pt;width:512.45pt;
  height:133.8pt;z-index:-15728128;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight="1pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:30.5pt;text-indent:-7.75pt;
     line-height:12.3pt;mso-line-height-rule:exactly;mso-list:l1 level1 lfo6;
     tab-stops:30.5pt'><![if !supportLists]><span style='font-family:Symbol;
     mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
     style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
     mso-bidi-font-family:Calibri'>The<span style='letter-spacing:-.3pt'> </span>National<span
     style='letter-spacing:-.2pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.25pt'> </span>Centre<span style='letter-spacing:
     -.35pt'> </span><span style='letter-spacing:-.1pt'>(NPC):</span><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:9.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:34.35pt;margin-bottom:.0001pt;text-indent:-8.85pt;
     mso-list:l9 level1 lfo5;tab-stops:34.35pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
     mso-bidi-font-family:Calibri'>SFDA<span style='letter-spacing:-.35pt'> </span>Call<span
     style='letter-spacing:-.15pt'> </span>Center:<span style='letter-spacing:
     -.1pt'> </span><span style='letter-spacing:-.2pt'>19999</span><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:9.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:31.6pt;margin-bottom:.0001pt;text-indent:-8.85pt;
     mso-list:l9 level1 lfo5;tab-stops:31.6pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
     mso-bidi-font-family:Calibri'>E-mail:<span style='letter-spacing:-.4pt'> </span></span><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"Times New Roman",serif;
     mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri;color:#0462C1;
     letter-spacing:-.1pt'>npc.drug@sfda.gov.sa</span></a><span
     style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
     mso-bidi-font-family:Calibri'><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:9.1pt;margin-right:0in;margin-bottom:
     0in;margin-left:34.35pt;margin-bottom:.0001pt;text-indent:-8.85pt;
     mso-list:l9 level1 lfo5;tab-stops:34.35pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span></span><![endif]><span dir=LTR></span><span
     style='font-family:"Times New Roman",serif;mso-hansi-font-family:Calibri;
     mso-bidi-font-family:Calibri'>Website:<span style='letter-spacing:-.25pt'>
     </span><u style='text-underline:#0462C1'><span style='color:#0462C1;
     letter-spacing:-.1pt'>https://ade.sfda.gov.sa/</span></u><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="688" height="183" alt="Text Box: •	The National Pharmacovigilance Centre (NPC):
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa/
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp; <strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_3" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:50pt;margin-top:13.75pt;width:512.45pt;height:42.35pt;z-index:-15727616;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAjqy2LHQDAADvFQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWNtO4zAQfV9p/8HyOzSXlqKKgLgs
aCXEVhQ+YOo6jbWOnbXd0vL1O3YSKF1tJS59S1ETO54enzkeD86cnK1KSZbcWKFVRuPDiBKumJ4J
Nc/o48P1wTEl1oGagdSKZ3TNLT07/f7tBEZzA1UhGEEEZUeQ0cK5atTrWVbwEuyhrrjCsVybEhx2
zbw3M/CEyKXsJVF01CtBKHr6CnUFDsjCiA9ASc1+89klqCVYhJRstPmk4SjZ55FhpJY3pppUY+OZ
s7vl2BAxyygqp6BEiWivGWjMsNvb+tX8FWCVm9Lb6zwnq4wepYMoQqh1RgdpOoyHgxqOrxxhfnwQ
HcfxgBIWLIbH/caAFb92I7Dix24MJFmTwcYGQVt5emr5r8dp6/EDspvqFUlfXPfGxK0uNFKOwxLb
6haXyNZioGo1XBCmRbaNpl8jyYs7MKqMdTdcl8Q3Mmo4c4ETLG+tqxm1Jt5XqcgT0k6GuBC+b7UU
s2shZeiY+fRSGrIEiWsePt5rnO2Nmce7AlvUdmGoMZOqtm6cdatJENiLNVv7GaZ4R/VwU7pfeMml
RjZMioqSQpvn7WdPuA0zav8swHBK5E9lQyy6tmHaxrRtGCcvtWcfvFP6fOF0Lhoh6tmDDNZN3Fpy
9A4lDBekVYK5zWgyTKMBhin27lsgW7ELnns7bI2drV3vo4iNPpvj57nbttywC6MoaaOR8aYGJ5fg
0xJXB48TTEvPuEhxs0Y8z3FV6+XEFQQnFHHriufAcEtO1uVUS0oqUNpiH7kPojhK8DuMjvA+iIY4
KhwrrqEUEvdWjImPFWAsx4hJ6sDmsIF5CVJMjdgATaJrBErCXz9K8d7fAk3xwQto6y865v1zpwc+
ilAWvNYe73aboMwZPcBk4O12C/AgSm7JHX8i97oE9YZ0ggr41ewH8uk/pN8oEUjjbF+vBOZSu1d5
yfvk7UStN8LumB1LDpa/T9kucN+XF7rApV+fbJlWDpj7UOQmXcpt/03uzg5d5O4hcl3xsXyb1ue9
7qCQ0S5qt8+hez99GS75EtTHEm7chW6XcP93HN176DJdVtzxLnb3/H4GC4cFDuHWh1unMq5mYzBw
/4kKwNccIPfy4ouv+68Ohrd/LLb4SsBLRWhh+aS6x/pGXUipS0Zo4Utzva1SZ/hpU5r19dTN/ulf
AAAA//8DAFBLAwQUAAYACAAAACEA4VE3H88GAADmGwAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVt
ZTEueG1s7FnNb9xEFL8j8T+MfG+z381G3VTZzW4Dbdoo2Rb1OGvP2tOMPdbMbNK9ofaIhIQoiAOV
uHFAQKVW4lL+mkARFKn/Am9mbK8n65C0jaCC5pC1n3/zvt+br8tX7sUMHRAhKU96Xv1izUMk8XlA
k7Dn3RqPLqx6SCqcBJjxhPS8OZHelfX337uM13xG0wnHIhhHJCYIGCVyDfe8SKl0bWVF+kDG8iJP
SQLfplzEWMGrCFcCgQ9BQMxWGrVaZyXGNPHWgaPSjIYM/iVKaoLPxJ5mQ1CCY5B+czqlPjHYYL+u
EXIuB0ygA8x6HvAM+OGY3FMeYlgq+NDzaubPW1m/vILXskFMnTC2NG5k/rJx2YBgv2FkinBSCK2P
Wt1LmwV/A2BqGTccDgfDesHPALDvg6VWlzLP1mi13s95lkD2cZn3oNautVx8iX9zSeduv99vdzNd
LFMDso+tJfxqrdPaaDh4A7L49hK+1d8YDDoO3oAsvrOEH13qdlou3oAiRpP9JbQO6GiUcS8gU862
KuGrAF+tZfAFCrKhyC4tYsoTdVKuxfguFyMAaCDDiiZIzVMyxT7k5ADHE0GxFoDXCC59sSRfLpG0
LCR9QVPV8z5MceKVIC+fff/y2RN0dP/p0f2fjh48OLr/o2XkjNrCSVge9eLbz/589DH648k3Lx5+
UY2XZfyvP3zyy8+fVwOhfBbmPf/y8W9PHz//6tPfv3tYAd8QeFKGj2lMJLpBDtEuj8Ew4xVXczIR
rzZiHGFaHrGRhBInWEup4D9UkYO+Mccsi46jR5+4HrwtoH1UAa/O7joK70VipmiF5GtR7AC3OWd9
Liq9cE3LKrl5PEvCauFiVsbtYnxQJXuAEye+w1kKfTNPS8fwQUQcNXcYThQOSUIU0t/4PiEV1t2h
1PHrNvUFl3yq0B2K+phWumRMJ042LQZt0RjiMq+yGeLt+Gb7NupzVmX1JjlwkVAVmFUoPybMceNV
PFM4rmI5xjErO/w6VlGVkntz4ZdxQ6kg0iFhHA0DImXVmJsC7C0F/RqGjlUZ9m02j12kUHS/iud1
zHkZucn3BxGO0yrsHk2iMvYDuQ8pitEOV1Xwbe5WiH6HOODkxHDfpsQJ9+nd4BYNHZUWCaK/zISO
JbRqpwPHNPm7dswo9GObA+fXjqEBPv/6UUVmva2NeAPmpKpK2DrWfk/CHW+6Ay4C+vb33E08S3YI
pPnyxPOu5b5rud5/vuWeVM9nbbSL3gptV68b7KLYLJHjE1fIU8rYnpozcl2aRbKEeSIYAVGPMztB
UuyY0gges77u4EKBzRgkuPqIqmgvwikssOueZhLKjHUoUcolbOwMuZK3xsMiXdltYVtvGGw/kFht
88CSm5qc7wsKNma2Cc3mMxfU1AzOKqx5KWMKZr+OsLpW6szS6kY10+ocaYXJEMNl04BYeBMWIAiW
LeDlDuzFtWjYmGBGAu13O/fmYTFROM8QyQgHJIuRtns5RnUTpDxXzEkA5E5FjPQm7xSvlaR1Nds3
kHaWIJXFtU4Ql0fvTaKUZ/AiSrpuj5UjS8rFyRJ02PO67UbbQz5Oe94U9rTwGKcQdanXfJiFcBrk
K2HT/tRiNlW+iGY3N8wtgjocU1i/Lxns9IFUSLWJZWRTw3zKUoAlWpLVv9EGt56XATbTX0OL5iok
w7+mBfjRDS2ZTomvysEuUbTv7GvWSvlMEbEXBYdowmZiF0P4daqCPQGVcDRhOoJ+gXM07W3zyW3O
WdGVT68MztIxSyOctVtdonklW7ip40IH81ZSD2yr1N0Y9+qmmJI/J1PKafw/M0XPJ3BS0Ax0BHw4
lBUY6XrteVyoiEMXSiPqjwQsHEzvgGyBs1j4DEkFJ8jmV5AD/WtrzvIwZQ0bPrVLQyQozEcqEoTs
QFsy2XcKs3o2d1mWLGNkMqqkrkyt2hNyQNhY98COnts9FEGqm26StQGDO55/7ntWQZNQL3LK9eb0
kGLutTXwT698bDGDUW4fNgua3P+FihWzqh1vhudzb9kQ/WGxzGrlVQHCSlNBNyv711ThFada27GW
LG60c+UgissWA7FYEKVw3oP0P5j/qPCZvW3QE+qY70JvRXDRoJlB2kBWX7ALD6QbpCVOYOFkiTaZ
NCvr2mzppL2WT9bnvNIt5B5zttbsLPF+RWcXizNXnFOL5+nszMOOry3tRFdDZI+XKJCm+UbGBKbq
1mkbp2gS1nse3PxAoO/BE9wdeUBraFpD0+AJLoRgsWRvcXpe9pBT4LulFJhmTmnmmFZOaeWUdk6B
xVl2X5JTOtCp9BUHXLHpHw/ltxmwgstuP/Km6lzNrf8FAAD//wMAUEsDBBQABgAIAAAAIQCcZkZB
uwAAACQBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzhI/N
CsIwEITvgu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxqWgFB
p7yenOFw6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W5iKj
YUGquzTI9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501LV2B
iYZ9/SbeAAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAAAAAA
AABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAA
AAAAAAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAI6stix0AwAA7xUAAB8AAAAAAAAA
AAAAAAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAAACEA
4VE3H88GAADmGwAAGgAAAAAAAAAAAAAAAADRBQAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWxQ
SwECLQAUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAADYDAAAY2xpcGJvYXJkL2Ry
YXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAANsNAAAAAA==
" filled="f" strokeweight="1pt">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:4.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:21.5pt;margin-bottom:.0001pt'><span style='font-family:
     Symbol'>-</span><span style='font-family:"Times New Roman",serif;
     mso-bidi-font-family:Calibri;letter-spacing:-.15pt'> </span><span
     style='font-family:"Times New Roman",serif;mso-bidi-font-family:Calibri'>Please<span
     style='letter-spacing:-.15pt'> </span>contact<span style='letter-spacing:
     -.25pt'> </span>the<span style='letter-spacing:-.3pt'> </span>relevant<span
     style='letter-spacing:-.1pt'> </span>competent<span style='letter-spacing:
     -.1pt'> authority.</span><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="687" height="61" alt="Text Box: - Please contact the relevant competent authority." src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rare cases of overdose up to 1,960 mg have been reported. In case of overdose, the patient should be observed carefully for bleeding complications or other adverse reactions (see section &quot;Management of bleeding .)&quot;Due to limited absorption a ceiling effect with no further increase in average plasma exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above .</p><p>A specific reversal agent (andexanet alfa) antagonising the pharmacodynamic effect of rivaroxaban is available (refer to the Summary of Product Characteristics of andexanet alfa).</p><p>The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered .</p><p><u>Management of bleeding</u></p><p>&nbsp;</p><p>Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban administration should be delayed or treatment should be discontinued as appropriate.</p><p>Rivaroxaban has a half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised according to the severity and location of the haemorrhage.</p><p>Appropriate symptomatic treatment could be used as needed, such as mechanical compression (e.g. for severe epistaxis) ,surgical haemostasis with bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.</p><p>If bleeding cannot be controlled by the above measures, either the administration of a specific factor Xa inhibitor reversal agent (andexanet alfa), which antagonises the pharmacodynamic effect of rivaroxaban ,or a specific procoagulant agent, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa), should be considered. However, there is currently very limited clinical experience with the use of these medicinal products in individuals receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding. Depending on local availability, a consultation with a coagulation expert should be considered in case of major bleedings (see section 5.1).</p><p>Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. There is limited experience with tranexamic acid and no experience with aminocaproic acid and aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>5.1. Pharmacodynamic Properties</u></p><p>Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01</p><p><u>Mechanism of action</u></p><p>Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.</p><p><u>Pharmacodynamic effects</u></p><p>Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant. In</p><p>&nbsp;</p><p>patients undergoing major orthopaedic surgery, the 5/95 percentiles for PT (Neoplastin) 2 - 4 hours after tablet intake (i.e. at the time of maximum effect) ranged from 13 to 25 s (baseline values before surgery 12 to 15 s).</p><p>In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3- factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC .In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).</p><p>The activated partial thomboplastin time (aPTT) and HepTest are also prolonged dose- dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated rivaroxaban levels can be measured by calibrated quantitative anti-factor Xa tests (see section 5.2).</p><p><u>Clinical efficacy and safety</u></p><p><em>Prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</em></p><p>The rivaroxaban clinical programme was designed to demonstrate the efficacy of rivaroxaban for the prevention of VTE, i.e. proximal and distal deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing major orthopaedic surgery of the lower limbs. Over 9,500 patients (7,050 in total hip replacement surgery and 2,531 in total knee replacement surgery) were studied in controlled randomised double-blind phase III clinical studies, the RECORD- programme .</p><p>Rivaroxaban 10 mg once daily (od) started no sooner than 6 hours post-operatively was compared with enoxaparin 40 mg once daily started 12 hours pre-operatively.</p><p>In all three phase III studies (see table 4), rivaroxaban significantly reduced the rate of total VTE (any venographically detected or symptomatic DVT, non-fatal PE and death) and major VTE (proximal DVT ,non-fatal PE and VTE-related death), the pre-specified primary and major secondary efficacy endpoints. Furthermore, in all three studies the rate of symptomatic VTE (symptomatic DVT, non-fatal PE, VTE-related death) was lower in rivaroxaban treated patients compared to patients treated with enoxaparin.</p><p>The main safety endpoint, major bleeding, showed comparable rates for patients treated with rivaroxaban 10 mg compared to enoxaparin 40 mg.</p><p>Table 4: Efficacy and safety results from phase III clinical studies</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Image_x0020_4" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:430pt;height:245pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="573" height="327" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>The analysis of the pooled results of the phase III studies corroborated the data obtained in the individual studies regarding reduction of total VTE, major VTE and symptomatic VTE with rivaroxaban 10 mg once daily compared to enoxaparin 40 mg once daily.</p><p>In addition to the phase III RECORD programme, a post-authorisation, non-interventional, open- label cohort study (XAMOS) has been conducted in 17,413 patients undergoing major orthopaedic surgery of the hip or knee, to compare rivaroxaban with other pharmacological thromboprophylaxis (standard-of-care) under real-life setting. Symptomatic VTE occurred in 57 (0.6%) patients in the rivaroxaban group (n=8,778) and 88 (1.0%) of patients in the standard-of- care group (n=8,635; HR 0.63; 95% CI 0.43-0.91); safety population). Major bleeding occurred in 35 (0.4%) and 29 (0.3%) of patients in the rivaroxaban and standard-of-care groups (HR 1.10; 95% CI 0.67-1.80). Thus, the results were consistent with the results of the pivotal randomised studies.</p><p><em>Treatment of DVT, PE and prevention of recurrent DVT and PE</em></p><p>The rivaroxaban clinical programme was designed to demonstrate the efficacy of rivaroxaban in the initial and continued treatment of acute DVT and PE and prevention of recurrence.</p><p>Over 12,800 patients were studied in four randomised controlled phase III clinical studies (Einstein DVT, Einstein PE, Einstein Extension and Einstein Choice). and additionally a predefined pooled analysis of the Einstein DVT and Einstein PE studies was conducted. The overall combined treatment duration in all studies was up to 21 months .</p><p>In Einstein DVT 3,449 patients with acute DVT were studied for the treatment of DVT and the prevention of recurrent DVT and PE (patients who presented with symptomatic PE were excluded from this study) .The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>&nbsp;</p><p>For the initial 3 week treatment of acute DVT 15 mg rivaroxaban was administered twice daily. This was followed by 20 mg rivaroxaban once daily .</p><p>In Einstein PE, 4,832 patients with acute PE were studied for the treatment of PE and the prevention of recurrent DVT and PE. The treatment duration was for 3, 6 or 12 months depending on the clinical judgement of the investigator.</p><p>For the initial treatment of acute PE 15 mg rivaroxaban was administered twice daily for three weeks. This was followed by 20 mg rivaroxaban once daily .</p><p>In both the Einstein DVT and the Einstein PE study, the comparator treatment regimen consisted of enoxaparin administered for at least 5 days in combination with vitamin K antagonist treatment until the PT/INR was in therapeutic range (&ge; 2.0). Treatment was continued with a vitamin K antagonist dose-adjusted to maintain the PT/INR values within the therapeutic range of 2.0 to 3.0.</p><p>In Einstein Extension 1,197 patients with DVT or PE were studied for the prevention of recurrent DVT and PE. The treatment duration was for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism depending on the clinical judgment of the investigator. Rivaroxaban 20 mg once daily was compared with placebo .</p><p>Einstein DVT, PE and Extension used the same pre-defined primary and secondary efficacy outcomes. The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE. The secondary efficacy outcome was defined as the composite of recurrent DVT, non-fatal PE and all-cause mortality .</p><p>In Einstein Choice, 3,396 patients with confirmed symptomatic DVT and/or PE who completed</p><p>6-12 months of anticoagulant treatment were studied for the prevention of fatal PE or non-fatal symptomatic recurrent DVT or PE. Patients with an indication for continued therapeutic-dosed anticoagulation were excluded from the study. The treatment duration was up to 12 months depending on the individual randomisation date (median: 351 days). Rivaroxaban 20 mg once daily and rivaroxaban 10 mg once daily were compared with 100 mg acetylsalicylic acid once daily.</p><p>The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE .</p><p>In the Einstein DVT study (see Table 5) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p &lt; 0.0001 (test for non-inferiority); Hazard Ratio (HR): 0.680 (0.443 - 1.042), p=0.076 (test for superiority)). The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.67 ((95% CI: 0.47 - 0.95), nominal p value p=0.027) in favour of rivaroxaban. INR values were within the therapeutic range a mean of 60.3% of the time for the mean treatment duration of 189 days, and 55.4%, 60.1%, and 62.8% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 &ndash; 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction). Within the</p><p>&nbsp;</p><p>highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.69 (95% CI: 0.35 - 1.35).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) as well as the secondary safety outcome (major bleeding events) were similar for both treatment groups.</p><p>Table 5: Efficacy and safety results from phase III Einstein DVT</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>3,449 patients with symptomatic acute deep vein thrombosis</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Treatment dose and duration</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban</strong><strong> </strong><strong>a)</strong></p><p><strong>3, 6 or 12 months N=1,731</strong></p></td><td style="vertical-align:top"><p><strong>Enoxaparin/VKA</strong><strong>b)</strong><strong>&nbsp;</strong><strong>3, 6 or 12 months N=1,718</strong></p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE*</p></td><td style="vertical-align:top"><p>36</p><p>(2.1%)</p></td><td style="vertical-align:top"><p>51</p><p>(3.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>20</p><p>(1.2%)</p></td><td style="vertical-align:top"><p>18</p><p>(1.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>14</p><p>(0.8%)</p></td><td style="vertical-align:top"><p>28</p><p>(1.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic PE and DVT</p></td><td style="vertical-align:top"><p>1</p><p>(0.1%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>4</p><p>(0.2%)</p></td><td style="vertical-align:top"><p>6</p><p>(0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Major or clinically relevant non-major bleeding</p></td><td style="vertical-align:top"><p>139</p><p>(8.1%)</p></td><td style="vertical-align:top"><p>138</p><p>(8.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>14</p><p>(0.8%)</p></td><td style="vertical-align:top"><p>20</p><p>(1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a)&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>* </strong>p &lt; 0.0001 (non-inferiority to a prespecified HR of 2.0); HR: 0.680 (0.443 - 1.042), p=0.076 (superiority)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>In the Einstein PE study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); HR: 1.123 (0.749 &ndash; 1.684)) .The prespecified net clinical benefit (primary efficacy outcome plus major bleeding events) was reported with a HR of 0.849 ((95% CI: 0.633 - 1.139), nominal p value p= 0.275). INR values were within the therapeutic range a mean of 63% of the time for the mean treatment duration of 215 days, and 57%, 62%, and 65% of the time in the 3-, 6-, and 12-month intended treatment duration groups, respectively. In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 &ndash; 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction).</p><p>Within the highest tertile according to centre, the HR with rivaroxaban versus warfarin was 0.642 (95% CI: 0.277 - 1.484).</p><p>The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)). The incidence of the secondary safety outcome (major bleeding events) was lower in the rivaroxaban group (1.1%</p><p>&nbsp;</p><p>(26/2412)) than in the enoxaparin/VKA group (2.2% (52/2405)) with a HR 0.493 (95% CI: 0.308 - 0.789).</p><p>Table 6: Efficacy and safety results from phase III Einstein PE</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>4,832 patients with an acute symptomatic PE</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Treatment dose and duration</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban </strong><strong>a)</strong></p><p><strong>3, 6 or 12 months N=2,419</strong></p></td><td style="vertical-align:top"><p><strong>Enoxaparin/VKA</strong><strong>b) </strong><strong>3, 6 or 12 months N=2,413</strong></p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE*</p></td><td style="vertical-align:top"><p>50</p><p>(2.1%)</p></td><td style="vertical-align:top"><p>44</p><p>(1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>23</p><p>(1.0%)</p></td><td style="vertical-align:top"><p>20</p><p>(0.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>18</p><p>(0.7%)</p></td><td style="vertical-align:top"><p>17</p><p>(0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic PE and DVT</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p><p>(&lt;0.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>11</p><p>(0.5%)</p></td><td style="vertical-align:top"><p>7</p><p>(0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Major or clinically relevant non- major bleeding</p></td><td style="vertical-align:top"><p>249</p><p>(10.3%)</p></td><td style="vertical-align:top"><p>274</p><p>(11.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>26</p><p>(1.1%)</p></td><td style="vertical-align:top"><p>52</p><p>(2.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a)&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p>* p &lt; 0.0026 (non-inferiority to a prespecified HR of 2.0); HR: 1.123 (0.749 - 1.684)</p></td></tr></tbody></table><p>A prespecified pooled analysis of the outcome of the Einstein DVT and PE studies was conducted (Table 7).</p><p>Table 7: Efficacy and safety results from pooled analysis of phase III Einstein DVT and Einstein PE</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>8,281 patients with an acute symptomatic DVT or PE</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Treatment dose and duration</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban </strong><strong>a)</strong></p><p><strong>3, 6 or 12 months N=4,150</strong></p></td><td style="vertical-align:top"><p><strong>Enoxaparin/VKA</strong><strong>b) </strong><strong>3, 6 or 12 months N=4,131</strong></p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE*</p></td><td style="vertical-align:top"><p>86</p><p>(2.1%)</p></td><td style="vertical-align:top"><p>95</p><p>(2.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>43</p><p>(1.0%)</p></td><td style="vertical-align:top"><p>38</p><p>(0.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>32</p><p>(0.8%)</p></td><td style="vertical-align:top"><p>45</p><p>(1.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic PE and DVT</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(&lt;0.1%)</p></td><td style="vertical-align:top"><p>(&lt;0.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>15</p><p>(0.4%)</p></td><td style="vertical-align:top"><p>13</p><p>(0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Major or clinically relevant non- major bleeding</p></td><td style="vertical-align:top"><p>388</p><p>(9.4%)</p></td><td style="vertical-align:top"><p>412</p><p>(10.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>40</p><p>(1.0%)</p></td><td style="vertical-align:top"><p>72</p><p>(1.7%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a)&nbsp; Rivaroxaban 15 mg twice daily for 3 weeks followed by 20 mg once daily</p><p>b)&nbsp; Enoxaparin for at least 5 days, overlapped with and followed by VKA</p><p><strong>* </strong>p &lt; 0.0001 (non-inferiority to a prespecified HR of 1.75); HR: 0.886 (0.661 - 1.186)</p></td></tr></tbody></table><p>The pre-specified net clinical benefit (primary efficacy outcome plus major bleeding events) of the pooled analysis was reported with a HR of 0.771 ((95% CI: 0.614 - 0.967), nominal p value p</p><p>= 0.0244).</p><p>In the Einstein Extension study (Table 9) Rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes. For the primary safety outcome (major bleeding events) there was a nonsignificant numerically higher incidence rate for patients treated with Rivaroxaban 20 mg once daily compared to placebo. The secondary safety outcome (major or clinically relevant non-major bleeding events) showed higher rates for patients treated with Rivaroxaban 20 mg once daily compared to placebo.</p><p>Table 8: Efficacy and safety results from phase III Einstein Extension</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>1,197 patients continued treatment and prevention of recurrent venous thromboembolism</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Treatment dose and duration</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban </strong><strong>a) </strong><strong>6 or 12 months N=602</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>6 or 12 months N=594</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Symptomatic recurrent VTE*</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>42</p></td></tr><tr><td style="vertical-align:top"><p>(1.3%)</p></td><td style="vertical-align:top"><p>(7.1%)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>13</p></td></tr><tr><td style="vertical-align:top"><p>(0.3%)</p></td><td style="vertical-align:top"><p>(2.2%)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>31</p></td></tr><tr><td style="vertical-align:top"><p>(0.8%)</p></td><td style="vertical-align:top"><p>(5.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>be ruled out</p></td><td style="vertical-align:top"><p>(0.2%)</p></td><td style="vertical-align:top"><p>(0.2%)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>(0.7%)</p></td><td style="vertical-align:top"><p>(0.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Clinically relevant non-major</p></td><td style="vertical-align:top"><p>32</p></td><td style="vertical-align:top"><p>7</p></td></tr><tr><td style="vertical-align:top"><p>bleeding</p></td><td style="vertical-align:top"><p>(5.4%)</p></td><td style="vertical-align:top"><p>(1.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a) Rivaroxaban 20 mg once daily</p><p><strong>* </strong>p &lt; 0.0001 (superiority), HR: 0.185 (0.087 - 0.393)</p></td></tr></tbody></table><p>&nbsp;</p><p>In the Einstein Choice study (see Table 9) rivaroxaban 20 mg and 10 mg were both superior to 100 mg acetylsalicylic acid for the primary efficacy outcome. The principal safety outcome (major bleeding events) was similar for patients treated with rivaroxaban 20 mg and 10 mg once daily compared to 100 mg acetylsalicylic acid.</p><p>Table 9: Efficacy and safety results from phase III Einstein Choice</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Study population</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>3,396 patients continued prevention of recurrent venous thromboembolism</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Treatment dose</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban 20 mg once daily</strong></p><p><strong>N=1,107</strong></p></td><td style="vertical-align:top"><p><strong>Rivaroxaban 10 mg once daily</strong></p><p><strong>N=1,127</strong></p></td><td style="vertical-align:top"><p><strong>ASA 100 mg once daily</strong></p><p><strong>N=1,131</strong></p></td></tr><tr><td style="vertical-align:top"><p>Treatment duration median [interquartile range]</p></td><td style="vertical-align:top"><p>349 [189-362] days</p></td><td style="vertical-align:top"><p>353 [190-362] days</p></td><td style="vertical-align:top"><p>350 [186-362] days</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE</p></td><td style="vertical-align:top"><p>17 (1.5%)*</p></td><td style="vertical-align:top"><p>13 (1.2%)**</p></td><td style="vertical-align:top"><p>50</p><p>(4.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent PE</p></td><td style="vertical-align:top"><p>6</p><p>(0.5%)</p></td><td style="vertical-align:top"><p>6</p><p>(0.5%)</p></td><td style="vertical-align:top"><p>19</p><p>(1.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent DVT</p></td><td style="vertical-align:top"><p>9</p><p>(0.8%)</p></td><td style="vertical-align:top"><p>8</p><p>(0.7%)</p></td><td style="vertical-align:top"><p>30</p><p>(2.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Fatal PE/death where PE cannot be ruled out</p></td><td style="vertical-align:top"><p>2</p><p>(0.2%)</p></td><td style="vertical-align:top"><p>0</p><p>(0.0%)</p></td><td style="vertical-align:top"><p>2</p><p>(0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE, MI, stroke, or non-CNS systemic embolism</p></td><td style="vertical-align:top"><p>19</p><p>(1.7%)</p></td><td style="vertical-align:top"><p>18</p><p>(1.6%)</p></td><td style="vertical-align:top"><p>56</p><p>(5.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding events</p></td><td style="vertical-align:top"><p>6</p><p>(0.5%)</p></td><td style="vertical-align:top"><p>5</p><p>(0.4%)</p></td><td style="vertical-align:top"><p>3</p><p>(0.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Clinically relevant non-major bleeding</p></td><td style="vertical-align:top"><p>30</p><p>(2.7)</p></td><td style="vertical-align:top"><p>22</p><p>(2.0)</p></td><td style="vertical-align:top"><p>20</p><p>(1.8)</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic recurrent VTE or major bleeding (net clinical benefit)</p></td><td style="vertical-align:top"><p>23</p><p>(2.1%)+</p></td><td style="vertical-align:top"><p>17</p><p>(1.5%)++</p></td><td style="vertical-align:top"><p>53</p><p>(4.7%)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* p&lt;0.001(superiority) rivaroxaban 20 mg od vs ASA 100 mg od; HR=0.34 (0.20-0.59)</p><p>** p&lt;0.001 (superiority) rivaroxaban 10 mg od vs ASA 100 mg od; HR=0.26 (0.14-0.47)</p><p>+ Rivaroxaban 20 mg od vs ASA 100 mg od; HR=0.44 (0.27-0.71), p=0.0009 (nominal)</p><p>++ Rivaroxaban 10 mg od vs ASA 100 mg od; HR=0.32 (0.18-0.55), p&lt;0.0001 (nominal)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>In addition to the phase III EINSTEIN programme, a prospective, non-interventional, open-label cohort study (XALIA) with central outcome adjudication including recurrent VTE, major bleeding and death has been conducted. 5,142 patients with acute DVT were enrolled to investigate the long-term safety of Rivaroxaban compared with standard-of-care anticoagulation therapy in clinical practice. Rates of major bleeding, recurrent VTE and all-cause mortality for Rivaroxaban</p><p>&nbsp;</p><p>were 0.7%, 1.4% and 0.5%, respectively. There were differences in patient baseline characteristics including age, cancer and renal impairment. A pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results. Adjusted HRs comparing Rivaroxaban and standard-of-care for major bleeding, recurrent VTE and all-cause mortality were 0.77 (95% CI 0.40 - 1.50), 0.91 (95% CI 0.54 - 1.54) and 0.51 (95% CI 0.24 - 1.07), respectively.</p><p>These results in clinical practice are consistent with the established safety profile in this indication.</p><p><u>Patients with high risk triple positive antiphospholipid syndrome</u></p><p>In an investigator sponsored, randomised open-label multicentre study with blinded endpoint adjudication, rivaroxaban was compared to warfarin in patients with a history of thrombosis, diagnosed with antiphospholipid syndrome and at high risk for thromboembolic events (positive for all 3 antiphospholipid tests: lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies). The study was terminated prematurely after the enrolment of 120 patients due to an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. 59 patients were randomised to rivaroxaban 20 mg (15 mg for patients with creatinine clearance (CrCl) &lt; 50 mL/min) and 61 to warfarin (INR 2.0-3.0).</p><p>Thromboembolic events occurred in 12% of patients randomised to rivaroxaban (4 ischaemic strokes and 3 myocardial infarctions). No events were reported in patients randomised to warfarin. Major bleeding occurred in 4 patients (7%) of the rivaroxaban group and 2 patients (3%) of the warfarin group.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Rivaroxaban in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Rivaroxaban is rapidly absorbed with maximum concentrations (Cmax) appearing 2 - 4 hours after tablet intake.</p><p>Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or Cmax at the 2.5 mg and 10 mg dose. Rivaroxaban 2.5 mg and 10 mg tablets can be taken with or without food. Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose.</p><p>This is more marked in fasting state than in fed state .Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%, apart from on the day of surgery and the following day when variability in exposure is high (70%).</p><p>&nbsp;</p><p>Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and Cmax compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.</p><p>Bioavailability (AUC and Cmax) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose- proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.</p><p>Distribution</p><p>Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with Vssbeing approximately 50 litres.</p><p>Biotransformation and elimination</p><p>Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.</p><p>Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation .Based on in vitroinvestigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).</p><p>Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.</p><p><u>Special populations</u></p><p><em>Gender</em></p><p>There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.</p><p><em>Elderly population</em></p><p>&nbsp;</p><p>Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.</p><p><em>Different weight categories</em></p><p>Extremes in body weight (&lt; 50 kg or &gt; 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.</p><p><em>Inter-ethnic differences</em></p><p>No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.</p><p><em>Hepatic impairment</em></p><p>Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold.</p><p>These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.</p><p>The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT .</p><p>Rivaroxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).</p><p><em>Renal impairment</em></p><p>There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min) ,moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance &lt; 15 ml/min.</p><p>Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p><p>&nbsp;</p><p>Use is not recommended in patients with creatinine clearance &lt; 15 ml/min. Rivaroxaban is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).</p><p><em>Pharmacokinetic data in patients</em></p><p>In patients receiving rivaroxaban for prevention of VTE 10 mg once daily the geometric mean concentration (90% prediction interval) 2 - 4 h and about 24 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 101 (7 - 273) and 14 (4 - 51) mcg/l, respectively.</p><p><em>Pharmacokinetic/pharmacodynamic</em><em> </em><em>relationship</em></p><p>The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor Xa activity was best described by an Emax model .For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcg/l). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects. In patients, baseline factor Xa and PT were influenced by the surgery resulting in a difference in the concentration-PT slope between the day post-surgery and steady state .</p><p>Paediatric population</p><p>Safety and efficacy have not been established in the indication primary prevention of VTE for children and adolescents up to 18 years .</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>5.3 Preclinical safety data</u></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.</p><p>Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.</p><p>In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications) .Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations .In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1 <u>&nbsp;</u><u>Excipients List</u></p><p>&nbsp;</p><p>Roxban 10 mg Filmcoated Tablets:</p><p>Microcrystalline Cellulose, Croscarmellose sodium, Lactose Monohydrate, Hypromellose, Sodium Laurilsulfate, Magnesium Stearate, Coating material for 10 mg Opadry Pink 03F240042</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.2. Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Roxban 10:</p><p>PVC/PE/PVDC White Opaque/ Aluminum Foil Blister of 10 tablets; cartons of 30 tablets (3 blisters)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA PHARMA:
Hail Industrial City MODON, Street No 32 PO Box 6979, Hail 55414
Kingdom of Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>